topotecan has been researched along with capecitabine in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
McCann, J | 1 |
Punt, CJ | 1 |
Ratain, MJ | 1 |
Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C | 1 |
Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
Cao, KI; Kirova, YM | 1 |
Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
3 review(s) available for topotecan and capecitabine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
2 trial(s) available for topotecan and capecitabine
Article | Year |
---|---|
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2005 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
4 other study(ies) available for topotecan and capecitabine
Article | Year |
---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Labeling; Female; Fluorouracil; Humans; Kidney; Male; Prodrugs; Topotecan | 2002 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |